Japan-based Fujifilm Corporation (Fujifilm) announced on 29 March 2018 that it has signed a stock purchase agreement and is acquiring all the outstanding shares of US-based Irvine Scientific Sales Company (ISUS) and Japan-based IS Japan (ISJ).

Culture media contain the nutrients required for the growth and proliferation of cells – and are essential for cell culturing in the R & D and manufacturing of biologicals. Fujifilm says the market for cell culture media is expanding following the dramatic growth in the demand for biologicals and expects annual growth of 10% going forward.

The businesses will be incorporated into Fujifilm’s existing contract development manufacturing organization (CDMO) unit Fujifilm Diosynth Biotechnologies. The acquisitions will enhance Fujifilm’s portfolio of cell culture media products and allow it to offer products for biologicals production, in vitro fertilization and cell therapy. The deal will also increase the company’s distribution capabilities in Europe and the US.

Fujifilm acquired Wako Pure Chemical Industries, a leading reagent manufacturer, in April 2017 to enter the cell culture media market; and acquired Cellular Dynamics International, a biotechnology firm, to expand its healthcare offerings.

Related articles
EMA accepts application for adalimumab biosimilar from Fujifilm Kyowa Kirin Biologics

AstraZeneca and Fujifilm Kyowa Kirin Biologics to collaborate on bevacizumab biosimilar

Fujifilm and Kyowa in biosimilars joint venture

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.